Serotonin 4 receptor (5-HT4R) internalization is isoform-specific: effects of 5-HT and RS67333 on isoforms A and B.
Serotonin 4 receptors (5-HT4Rs) are particularly abundant within the limbic system, where they constitute potential targets for the development of novel, rapid acting antidepressants. However, the population of limbic 5-HT4Rs is not homogenous, comprising various isoforms of which 5-HT4(a) and 5-HT4(b) are among the most abundant variants. Sequence divergence at their C-termini is predictive of specificity in isoform signalling and regulation, but the differences, if any, remain ill-defined. The present study compared isoforms 5-HT4(a) and 5-HT4(b) in their ability to undergo endocytic regulation following exposure to 5-HT and to the putatively fast acting antidepressant RS67333. Both ligands differed in their ability to induce internalization of either isoform, 5-HT being more effective than RS67333 in HEK293 cells and in neurons. In contrast, trafficking induced by 5-HT was isoform-specific. In particular, while PKC, GRK2 and betaarrestin were necessary for 5-HT4(a)R internalization, sequestration of 5-HT4(b)Rs required PKC but not GRK2 and relied significantly less on betaarrestin. After endocytosis, isoform (b) appeared scattered throughout the intracellular compartment and efficiently recycled to the membrane upon agonist removal. Isoform (a) accumulated in the perinuclear compartment and displayed little recycling. Isoform-specific subcellular distribution was present in HEK293 cells and in neurons. In neurons, where internalization by RS67333 was more pronounced than in HEK293 cells, receptors internalized by this ligand followed the same distribution pattern as observed with 5-HT. These results point to isoform-related differences in the way that 5-HTRs respond to different ligands. Such diversity should be taken into account when developing therapeutic agents that target 5-HT4Rs.
Mnie-Filali
O
O
Department of Pharmacology, Faculty of Medicine, University of Montreal, and Centre de Recherche de l'Hôpital Ste Justine, Montreal, Quebec, Canada.
Amraei
M Gholi
MG
Benmbarek
S
S
Archer-Lahlou
E
E
Peñas-Cazorla
R
R
Vilaró
M T
MT
Boye
S M
SM
Piñeyro
G
G
D000814:Aniline Compounds / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D019390:Arrestins / Q000378:metabolism; D002478:Cells, Cultured; D004705:Endocytosis; D054769:G-Protein-Coupled Receptor Kinase 2 / Q000378:metabolism; D006801:Humans; D009474:Neurons / Q000166:cytology; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology*; D020033:Protein Isoforms / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism; D051381:Rats; D044422:Receptors, Serotonin, 5-HT4 / Q000378:metabolism*; D012701:Serotonin / Q000494:pharmacology*; D058828:Serotonin 5-HT4 Receptor Agonists; D000071557:beta-Arrestins
D000814:Aniline Compounds; D000928:Antidepressive Agents; D019390:Arrestins; D010880:Piperidines; D020033:Protein Isoforms; D058828:Serotonin 5-HT4 Receptor Agonists; D000071557:beta-Arrestins; D044422:Receptors, Serotonin, 5-HT4; C107826:RS 67333; D012701:Serotonin; D011493:Protein Kinase C; C496567:GRK2 protein, human; D054769:G-Protein-Coupled Receptor Kinase 2